Uterine sarcoma 2008

Jeff F. Lin, Brian Slomovitz

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

Uterine sarcomas are a group of rare and usually aggressive soft tissue cancers. They have a wide range of histologic appearances, from myomatous to osteous to stromal. The three major subtypes of uterine sarcomas (listed in decreasing order of incidence) are carcinosarcoma, leiomyosarcoma, and endometrial stromal sarcoma. Most patients with uterine sarcomas are middle-to older-aged women who present with abnormal uterine bleeding or pelvic mass, which may be confused with leiomyoma. Surgery - including hysterectomy and resection of disease - serves as the main treatment modality. Adjuvant therapies, including radiation, chemotherapy, and/or hormonal therapy, have limited benefit on overall survival; however, this may be due to the lack of good randomized controlled trials of sufficient size because of uterine sarcomas' rare and aggressive nature. For patients with metastatic recurrent disease, aggressive therapy is limited by low response rates and limited duration of response. For patients with uterine sarcomas, enrollment in clinical trials is strongly encouraged.

Original languageEnglish (US)
Pages (from-to)512-518
Number of pages7
JournalCurrent Oncology Reports
Volume10
Issue number6
DOIs
StatePublished - 2008
Externally publishedYes

Fingerprint

Sarcoma
Endometrial Stromal Sarcoma
Carcinosarcoma
Leiomyosarcoma
Uterine Hemorrhage
Leiomyoma
Hysterectomy
Radiotherapy
Therapeutics
Randomized Controlled Trials
Clinical Trials
Drug Therapy
Survival
Incidence
Neoplasms

ASJC Scopus subject areas

  • Oncology

Cite this

Uterine sarcoma 2008. / Lin, Jeff F.; Slomovitz, Brian.

In: Current Oncology Reports, Vol. 10, No. 6, 2008, p. 512-518.

Research output: Contribution to journalArticle

Lin, Jeff F. ; Slomovitz, Brian. / Uterine sarcoma 2008. In: Current Oncology Reports. 2008 ; Vol. 10, No. 6. pp. 512-518.
@article{32937d36706c4175b63e876fc13947ff,
title = "Uterine sarcoma 2008",
abstract = "Uterine sarcomas are a group of rare and usually aggressive soft tissue cancers. They have a wide range of histologic appearances, from myomatous to osteous to stromal. The three major subtypes of uterine sarcomas (listed in decreasing order of incidence) are carcinosarcoma, leiomyosarcoma, and endometrial stromal sarcoma. Most patients with uterine sarcomas are middle-to older-aged women who present with abnormal uterine bleeding or pelvic mass, which may be confused with leiomyoma. Surgery - including hysterectomy and resection of disease - serves as the main treatment modality. Adjuvant therapies, including radiation, chemotherapy, and/or hormonal therapy, have limited benefit on overall survival; however, this may be due to the lack of good randomized controlled trials of sufficient size because of uterine sarcomas' rare and aggressive nature. For patients with metastatic recurrent disease, aggressive therapy is limited by low response rates and limited duration of response. For patients with uterine sarcomas, enrollment in clinical trials is strongly encouraged.",
author = "Lin, {Jeff F.} and Brian Slomovitz",
year = "2008",
doi = "10.1007/s11912-008-0077-9",
language = "English (US)",
volume = "10",
pages = "512--518",
journal = "Current Oncology Reports",
issn = "1523-3790",
publisher = "Current Science, Inc.",
number = "6",

}

TY - JOUR

T1 - Uterine sarcoma 2008

AU - Lin, Jeff F.

AU - Slomovitz, Brian

PY - 2008

Y1 - 2008

N2 - Uterine sarcomas are a group of rare and usually aggressive soft tissue cancers. They have a wide range of histologic appearances, from myomatous to osteous to stromal. The three major subtypes of uterine sarcomas (listed in decreasing order of incidence) are carcinosarcoma, leiomyosarcoma, and endometrial stromal sarcoma. Most patients with uterine sarcomas are middle-to older-aged women who present with abnormal uterine bleeding or pelvic mass, which may be confused with leiomyoma. Surgery - including hysterectomy and resection of disease - serves as the main treatment modality. Adjuvant therapies, including radiation, chemotherapy, and/or hormonal therapy, have limited benefit on overall survival; however, this may be due to the lack of good randomized controlled trials of sufficient size because of uterine sarcomas' rare and aggressive nature. For patients with metastatic recurrent disease, aggressive therapy is limited by low response rates and limited duration of response. For patients with uterine sarcomas, enrollment in clinical trials is strongly encouraged.

AB - Uterine sarcomas are a group of rare and usually aggressive soft tissue cancers. They have a wide range of histologic appearances, from myomatous to osteous to stromal. The three major subtypes of uterine sarcomas (listed in decreasing order of incidence) are carcinosarcoma, leiomyosarcoma, and endometrial stromal sarcoma. Most patients with uterine sarcomas are middle-to older-aged women who present with abnormal uterine bleeding or pelvic mass, which may be confused with leiomyoma. Surgery - including hysterectomy and resection of disease - serves as the main treatment modality. Adjuvant therapies, including radiation, chemotherapy, and/or hormonal therapy, have limited benefit on overall survival; however, this may be due to the lack of good randomized controlled trials of sufficient size because of uterine sarcomas' rare and aggressive nature. For patients with metastatic recurrent disease, aggressive therapy is limited by low response rates and limited duration of response. For patients with uterine sarcomas, enrollment in clinical trials is strongly encouraged.

UR - http://www.scopus.com/inward/record.url?scp=58649099573&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=58649099573&partnerID=8YFLogxK

U2 - 10.1007/s11912-008-0077-9

DO - 10.1007/s11912-008-0077-9

M3 - Article

C2 - 18928666

AN - SCOPUS:58649099573

VL - 10

SP - 512

EP - 518

JO - Current Oncology Reports

JF - Current Oncology Reports

SN - 1523-3790

IS - 6

ER -